Athira enters ATM stock offering; reports ~$245.2M cash as of Dec 31, 2022

LeonaBio, Inc.

Entered Sales Agreement with Cantor Fitzgerald & BTIG for at-the-market offering of common stock.
Agents to receive 3.0% of gross proceeds; Company has no obligation to sell any shares.
Preliminary cash, equivalents and investments total ~$245.2M as of Dec 31, 2022 (unaudited).
Shares to be issued under effective shelf registration statement on Form S-3 (File No. 333-261073).
Prospectus supplement dated Jan 6, 2023 filed with SEC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LeonaBio, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and BTIG, LLC valued at maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement (effective 2023-01-06).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co. and BTIG, LLC
Value: maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement
Effective: 2023-01-06

Exact text from the filing

On January 6, 2023, Athira Pharma, Inc, a Delaware corporation (the “Company”), entered into a Controlled Equity Offering Sales Agreement SM (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and BTIG, LLC (“BTIG” and together with Cantor, the “Agents” and each, an “Agent”).

View on SEC.gov

Browse all material agreements →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.